CAD 0.89
(-4.3%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | - CAD | 0.0% |
2022 | - CAD | 0.0% |
2021 | - CAD | 0.0% |
2020 | - CAD | -100.0% |
2019 | 25 Thousand CAD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | - CAD | 0.0% |
2024 Q2 | - CAD | 0.0% |
2023 Q3 | - CAD | 0.0% |
2023 FY | - CAD | 0.0% |
2023 Q2 | - CAD | 0.0% |
2023 Q1 | - CAD | 0.0% |
2023 Q4 | - CAD | 0.0% |
2022 Q4 | - CAD | 0.0% |
2022 FY | - CAD | 0.0% |
2022 Q3 | - CAD | 0.0% |
2021 FY | - CAD | 0.0% |
2020 FY | - CAD | -100.0% |
2019 FY | 25 Thousand CAD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Appili Therapeutics Inc. | 827.4 Thousand CAD | 100.0% |
Eupraxia Pharmaceuticals Inc. | - CAD | NaN% |
Helix BioPharma Corp. | - CAD | NaN% |
Microbix Biosystems Inc. | 16.51 Million CAD | 100.0% |
Medicenna Therapeutics Corp. | - CAD | NaN% |
Oncolytics Biotech Inc. | - CAD | NaN% |
Sernova Corp. | - CAD | NaN% |